Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comprehensive Characterization of the Tumor Immune Micromilieu and its Interference with Outcome After Concurrent Chemoradiation in Patients with Locally Advanced Oropharyngeal Carcinomas

ABSTRACT: Comprehensive Characterization of the Tumor Immune Micromilieu and its Interference with Outcome After Concurrent Chemoradiation in Patients with Locally Advanced Oropharyngeal Carcinomas

PROVIDER: PRJNA450649 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Comprehensive Characterization of the Tumor Immune Micromilieu and its Interference with Outcome After Concurrent Chemoradiation in Patients with Locally Advanced Oropharyngeal Carcinomas

Project description:Intratumoral CD8+ T-cell infiltration in squamous cell carcinoma of the head and neck (HNSCC) has previously been linked to the efficacy of chemoradiation (CRTX) and immune checkpoint inhibitor (ICI) monotherapy. Further detailed characterization of the tumor immune-micromilieu and its influence on outcome may suggest rational CRTX-ICI combinations. In this study, the complex interaction of the tumor immune microenvironment with the efficacy of CRTX in HNSCC was analyzed. Comprehensive immune transcriptome analysis of FFPE tumor samples from patients with oropharyngeal carcinoma was used for establishing differences in tumor immune profiles according to the overall survival status. Furthermore, a composite immune signature risk score for survival prediction was developed.

2019-05-02 | GSE113282 | GEO

High-throughput proteomic analysis of rectal cancer for prediction of non-complete response after concurrent chemoradiation therapy

Project description:Colorectal cancer (CRC) is the third most common lethal malignancy in Korea and worldwide. Rectal cancer patients occupy about 30% of CRC patients, and the majority of rectal cancer patients had locally advanced disease at diagnosis. The standard treatment of locally advanced rectal cancer (LARC) is neoadjuvant radiation therapy with concurrent chemotherapy (CCRT) followed by total mesorectal excision (TME). This multidisciplinary team approach improved local tumor control and overall survival of rectal cancer patients. High throughput proteomic analysis and machine learning algorithm identify DUOX2 (dual oxidase 2) as a novel biomarker for prediction of non-complete response after concurrent chemoradiation therapy for rectal cancer.High throughput proteomic analysis and machine learning algorithm identify DUOX2 (dual oxidase 2) as a novel biomarker for prediction of non-complete response after concurrent chemoradiation therapy for rectal cancer.

2023-03-11 | PXD023302 | Pride

microRNA profiling for prediction of chemoradiation efficacy in locally advanced head and neck squamous cell carcinoma

Project description:The predictive value of microRNAs for the efficacy of chemoradiation (CRTX) in locally advanced head and neck squamous cell carcinoma (HNSCC) was evaluated. Formalin-fixed, paraffin-embedded tumor material was collected from patients with locally advanced HNSCC treated within the ARO-0401 phase III trial with radiotherapy in combination with either 5-fluorouracil/cisplatin (CDDP-CRTX) or 5-fluorouracil/mitomycin C (MMC-CRTX).

2017-03-30 | E-MTAB-5198 | biostudies-arrayexpress

Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas.

Project description:BackgroundIntra-tumoral CD8 + T-cell infiltration in squamous cell carcinoma of the head and neck (HNSCC) has previously been linked to the efficacy of cisplatin-based chemoradiation (CDDP-CRTX) and immune checkpoint inhibitor (ICI) monotherapy. Further detailed characterization of the tumor immune-micromilieu and its influence on outcome may guide the development of CRTX-ICI combinations.MethodsComprehensive immune transcriptome analysis was applied to a training set of tumor specimens from oropharyngeal squamous cell carcinoma (OPSCC) patients treated with CDDP-CRTX in the ARO-0401 phase III study (n = 33). A composite immune signature risk score (ISRS) for survival prediction was developed, and subsequently validated in two independent OPSCC cohorts treated with either CDDP-CRTX (n = 36) or mitomycin-based CRTX (MMC-CRTX, n = 31). Further validation of the ISRS was performed in the OPSCC subset (n = 79) of the TCGA HNSCC cohort. Potential interference between immune signatures and HPV status was evaluated in multivariate Cox regression models.ResultsSignificant differences according to the 3-y OS status in the abundance of tumor-infiltrating T- and B-cells, and the expression levels of 51 immune-related genes were observed. A risk score based on 13 differentially expressed genes involved in cytokine signaling, T-cell effector functions and the TNFR pathway was established as robust predictive factor of OS. Its predictive power was superior to the 6-gene interferon-gamma signature of ICI efficacy and independent of the HPV status.ConclusionsThis study further elucidates the complex interaction of the tumor immune microenvironment with the efficacy of CDDP-CRTX in OPSCC. The results suggest immune markers for selection of patients treated with CRTX-ICI combinations.

| S-EPMC6682352 | biostudies-literature

Epigenetic therapy with hydralazine and magnesium valproate added to chemoradiation in cervical carcinoma.

Project description:As a number of epigenetic alterations have been described in cervical cancer which may participate in the development and progression of this tumor, and the primary treatment for locally advanced disease is concurrent chemoradiation, we wanted to evaluate the efficacy and safety of hydralazine and valproate added to radiation and cisplatin. In addition, the transcriptome changes induced by the epigenetic drugs were also evaluated. Keywords: Cervical Cancer, epigenetic therapy, valproate, hydralazine, transcriptional response, epigenetic drugs

2007-07-31 | GSE8604 | GEO

Enhancing Concurrent Chemoradiation Outcome Prediction for Locally Advanced Cervical Cancer Patients Through Plasma Extracellular Vesicle Proteomics Analysis

Project description:Majority of the patients with cervical cancer present with locally advanced cervical cancer (LACC), which is primarily treated using concurrent chemoradiation (CCRT) and lacks reliable predictive biomarkers. Extracellular vesicles (EVs) could potentially define the dynamic biological response to CCRT. However, the relationship between EVs and the therapeutic response to LACC is unestablished. This study aimed to determine the relationship of plasma EVs pre- and post-CCRT in 62 patients with LACC. EVs were isolated using ultracentrifugation (UC) with size exclusion chromatography or UC alone for proteomic analyses. The plasma particle concentration significantly increased post-treatment in non-responders. The viral control process was enhanced at 1 month and adaptive immune response increased at 3 months, following the standard clinical cut-off. Sparse partial least squares-discriminant analysis revealed 8, 13, and 19 proteins at diagnosis, 1 month, and 3 months, respectively, influencing the CCRT response. Among these, FIBG, TFR1, HBA, and FINC, are poor prognostic markers in the cancer genome atlas tissue gene expression database. The discriminant model demonstrated excellent specificity and negative predictive value. In conclusion, the validation of our model underscores its reliability in determining the responsiveness to CCRT, highlighting the potential clinical applicability of EVs in improving outcomes in LACC.

2024-09-30 | PXD050754 | JPOST Repository

Phosphoproteomics guides low dose drug combination of cisplatin and silmitasertib against concurrent chemoradiation resistant cervical cancer

Project description:Cervical cancer is one of the leading causes of cancer related deaths among females. Due to proper screening programmes, most of the cervical cancer cases are presented in the locally advanced stage of the disease. Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer. However, resistance to CCRT limit the success of the treatment regimen. In this study, we investigated the altered phosphoproteome of CCRT resistant and sensitive cohort using Mass spectrometry-based proteomics. We carried out phosphoproteomic analysis of treatment naïve cervical cancer patients whose response to CCRT is recorded. The Phosphoproteomic analysis revealed kinases and the pathways associated with CCRT resistance in cervical cancer patients.

2024-12-12 | PXD055164 | Pride

Clinical and genomic characterization of chemoradiation resistant HPV-positive squamous cell carcinoma

Project description:This study performed genomic sequencing on a rare phenotype of HPV-positive oropharyngeal squamous cell carcinoma which was resistant to standard of care platinum based chemoradiation treatment. Tissue was collected from archival FFPE when available from pretreatment and post treamtent samples from four patients and these were batch corrected to be compared to known HPV-positive tumors without recurrent disease

2024-02-23 | GSE256047 | GEO

Transcription profiling of untreated and cisplatin-based chemoradiation treated human squamous cell carcinomas to improve prediction of outcome after chemoradiation

Project description:Gene expression profiling to predict outcome after chemoradiation in head and neck cancer Purpose. The goal of the present study was to improve prediction of outcome after chemoradiation in advanced head and neck cancer using gene expression analysis. Materials and Methods. We collected 92 biopsies from untreated head and neck cancer patients subsequently given cisplatin-based chemoradiation (RADPLAT) for advanced squamous cell carcinomas (HNSCC). After RNA extraction and labeling we performed dye swap experiments using 35k oligo-microarrays. Supervised analyses were performed to create classifiers to predict local control, locoregional control and disease recurrence. Published gene sets with prognostic value in other studies were also tested. Results. Using supervised classification on the whole series, gene sets separating good and poor outcome could be found for all end-points. However, when splitting tumors into training and validation groups, no robust classifiers could be found. Also previously published signatures with prognostic value have been tested. Conclusion. Gene sets can be found with predictive potential for locoregional control after combined radiation and chemotherapy in HNSCC. How treatment-specific these gene sets are needs further study.

2008-02-19 | E-NCMF-8 | biostudies-arrayexpress

Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer

Project description:Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer

| PRJNA976474 | ENA